Edgewise Therapeutics files amended 8-K with unaudited pro forma financials for Servier asset sale
EWTX•Company now focused on cardiovascular pipeline
Following the asset sale, Edgewise said it has repositioned as a cardiovascular-focused company, with its pipeline centered on EDG-7500, EDG-15400, and EDG-003.
Pro forma balance sheet and 2025 results reflect the sale
The pro forma balance sheet as of March 31, 2026 reflected a net cash increase of USD 1.5 billion, lifting cash to USD 1.53 billion.
Pro forma 2025 results included a USD 1.49 billion pre-tax gain, an income tax expense of USD 259.84 million, and net income of USD 1.14 billion.
Amended 8-K updates pro forma financials for Servier asset sale
Edgewise Therapeutics filed an amended Form 8-K to update unaudited pro forma financials tied to the sevasemten program sale to Servier.
The transaction closed July 10, 2026, and consideration included USD 1.55 billion in upfront cash, plus up to USD 1.1 billion in milestones that were excluded from the pro forma statements.
